Every newborn receives an almost clean slate from their parents: during fertilization, the epigenomic marks that accumulated in the parents' cells under the influence of stress, nutrition, and toxins are erased thanks to a molecular reprogramming mechanism. This allows each generation to begin life with a cleansed epigenetic record—like a musician turning the page of a score, ready for a new melody. But what if we could replicate this natural restorative mechanism in adults when the epigenome is damaged by disease? Scientists are now attempting to do just that—not by altering the gene sequence itself, but by regulating gene activity.
This is about epigenome editing, or epigenetic editing—a technology for managing the molecular marks that attach to DNA and control gene activity. These chemical modifications—primarily DNA methylation and histone acetylation—accumulate under the influence of stress, nutrition, infections, and toxins, building up over years and decades. If DNA is the notes in a score, then the epigenome is the conductor's annotations, indicating where to play louder, where to skip a measure, and where to insert a pause. Unlike the genome, these marks constantly change throughout life in response to the environment and can increase the risk of chronic inflammation, asthma, cardiovascular diseases, and cancer.
Traditional gene editing tools, such as CRISPR/Cas9, make permanent changes directly to the 'nature'—the DNA sequence itself. These changes are persistent, passed on to the next generation, and require extreme caution. The new epigenome editing technology aims to correct not the genes but their 'environment'—the accumulated traces of environmental exposures and diseases—while leaving the DNA itself untouched.
Tune Therapeutics has already advanced furthest in testing this approach. Its drug TUNE-401 is the first epigenetic editor of its kind for treating chronic hepatitis B. The hepatitis B virus affects more than 240 million people worldwide, and current treatments rarely lead to a functional cure: less than one percent of patients achieve complete viral clearance per year. In early 2024, phase 1b/2a clinical trials began. And in June 2026, Tune Therapeutics presented initial data demonstrating epigenetic suppression of viral activity in patients' livers. The epigenome editor silences viral genes in liver cells without affecting either the patient's cellular DNA or the structure of the viral genome itself.
According to Fyodor Urnov, a leading gene editing expert and one of the co-founders of Tune Therapeutics, environmental factors indeed alter gene activity at the level of epigenomic marks. Similar approaches are being considered for lowering cholesterol and treating other cardiometabolic diseases: instead of blocking a protein or knocking out a gene, one can delicately 'turn down' the gene responsible for its production at the level of epigenetic marks. This opens the way to treating a whole class of diseases caused not by mutations or genetic defects, but by long-term consequences of lifestyle and environmental exposure.
However, it is important to soberly assess the limitations. So far, clinical data are limited to one drug in early-stage trials. The long-term effects of such intervention have yet to be studied. Unlike classical genome editing, changes in the epigenome appear to be reversible—this reduces the risk of irreversible harm but simultaneously requires repeated procedures or ongoing treatment. Research has not yet provided a complete picture of possible side effects on neighboring genes or other tissues in the body. There are also questions about the durability of the effect: will epigenetic changes persist for a long time after treatment is discontinued?
The ability to erase biological scars of the past—accumulated epigenomic damage from disease and stress—sounds promising, but it requires caution and thorough validation before widespread use. The technology does not eliminate the need for a healthy lifestyle, prevention, and immune strengthening. Rather, it complements the conventional medical arsenal with a new tool for cases where past damage has already been inflicted.
Ultimately, the success of epigenome editing will depend not only on the precision of the technology and its safety, but also on a deeper question: how ready is society to invest in early prevention and interventions at the pre-disease stage, rather than waiting until the disease takes hold and requires heroic rescue measures?
